By conducting OAE tests before, during, and after cancer treatment, healthcare providers can monitor changes in cochlear function. A decrease in the amplitude or absence of OAEs may indicate early signs of ototoxicity, allowing for timely intervention, such as adjusting the treatment regimen or using protective agents like amifostine.
